Zuellig Pharma in deal with Boryung for Kanarb in Southeast Asia

Zuellig Pharma has entered into an exclusive in-licensing agreement for Kanarb (fimasartan) in certain Southeast Asian countries with fellow Korean company Boryung Pharmaceutical.

This is the largest licensing agreement for the product anywhere in the world, said Zuellig, although financial terms of the accord were not disclosed.

Zuellig Pharma will launch and market the anti-hypertensive drug Kanarb in 13 Southeast Asian countries, with particular focus on Indonesia, Malaysia, Philippines, Singapore, Thailand and Vietnam. In addition, both parties intend to conclude a licensing agreement for Kanarb combination drugs (diuretics, CCB, rosuvastatin).